Effect of 2'-fluoro-5'-methyl-ara-uracil and cyclophosphamide on herpes simplex virus infection in guinea pigs

ZHENG Zhi-Ming*, M L LANDRY, D R MAYO†, G D HISIUNG
(Dept Laboratory Medicine, Yale University School of Medicine, New Haven CT 06516, USA)

ABSTRACT 1p 2'-fluoro-5'-methyl-ara-uracil (FMAU) 50 (mg/kg)/d for 5 d starting 3 d post-vaginal inoculation of HSV-2 almost completely inhibited the appearance of primary genital lesions (GL) but did not reduce the establishment of HSV latency. When 1p cyclophosphamide (Cy) 50 (mg/kg)/d for 5 d was simultaneously given, mild delayed GL were occasionally noticed in FMAU-treated animals. During HSV-2 latent infection, 1p Cy 50 (mg/kg)/d for 10 d could induce genital herpes recurrence in FMAU-treated animals. 1p Cy 100 (mg/kg)/dose for 3 doses at

Received 1985 May 2 Revised 1986 Aug 18 Present address: Virus Research Institute, Nabel Medical College, Wuhan 430071, China; Virus Laboratory, Connecticut State Health Department, Hartford CT 06104, USA.

This study was supported in part by contract N01-AL-12065 from NIH, Bethesda, MD and Veterans Administration Research Funds, USA weekly intervals could increase the incidence of recurrent GLs, suggesting that the reactivation of latent HSV by Cy was dosage related.

KEY WORDS 2'-fluoro-5'-methyl-ara-uracil, herpesvirus hominis; guinea pigs; drug therapy

FMAU (2'-fluoro-5'-methyl-ara-uracil) or 1-(2'-fluoro-5'-deoxy-β-D-arabinofuranosyl) thymine was synthesized by Watanabe et al.12 and showed potent antiviral activity in cell cultures13, encephalitis infections in mice14, acute keratitis in rabbits15, and primary acute genital herpes (GH) in guinea pigs16. However, it is unknown whether FMAU treatment of primary GH in guinea pigs can reduce or prevent the establishment of latent infection. This paper reports that FMAU, as other
antiviral agents could not eradicate HSV latency from nerve tissues even though treated guinea pigs did not show clinical lesions during acute infection.

**MATERIALS AND METHODS**

Virus and cells HSV-2 strain 1868 was originally isolated in our laboratory[14]. Virus stock was prepared in primary guinea pig embryo (GPE) cells and infectivity titers were determined by plaque formation in GPE cells.

Animals and virus inoculation Young Hartley guinea pigs were inoculated intravaginally with 10^4.4±1.1 PFU of HSV-2 strain 1868 and the genital lesions (GL) were scored[18].

Virus recovery from guinea pig vaginas Guinea pig vaginas were swabbed with pre-moistened cotton-tipped applicators which were then placed in a vial with 1.0 ml of minimal essential medium (MEM) containing Earle's balanced salt solution (EBSS), 2% calf serum and 10% (vol/vol) dimethylsulfoxide. All samples were frozen at -70°C until plaque assay in GPE cells.

FMAU treatment FMAU and drug vehicle solutions were kindly provided by Dr C McLaren (Bristol-Myers Co). FMAU was weighed and dissolved in the drug vehicle solution (20% propylene glycol, 25% ethanol and 55% water) at a concentration of 50 mg/ml. Then, the FMAU solution was sterilized by passing through a membrane filter. Guinea pigs were treated with ip FMAU twice daily at 9 am and 4 pm for 3 d. Sham-treated groups received drug vehicle solution only.

Cyclophosphamide treatment Cyclophosphamide (Cy) was purchased from Sigma Chemical Co and dissolved in PBS at a concentration of 50 mg/ml. The drug solution was sterilized with a 0.22-μm Millipore membrane filter and stored at 4°C.

In acute infection experiments, two groups of guinea pigs were treated ip with a single dose of Cy 50 (mg/kg)/d for 7 d and FMAU was added to one group simultaneously. For latent infection experiments, animals were infected and treated with FMAU ip during acute infection, approximately 20-183 d later. Half of the FMAU treated and half of the untreated groups received Cy 50 (mg/kg)/d for 10 d. The other half of each group received PBS ip only. In addition, several untreated animals were given Cy 50 (mg/kg)/d for 10 d or three doses of 300 (mg/kg)/dose at weekly intervals to determine if there was a dosage response to Cy reactivation. All animals were checked daily for recurrent lesions and virus shedding in the vagina was monitored every three days for 28 d.

Isolation of latent virus from spinal cord and ganglia All animals with and without recurrent herpes were sacrificed at the end of each experiment. Spinal cord (SC) and lumbar dorsal root ganglia (DRG) were removed aseptically, minced in MEM containing EBSS and 2% calf serum, then cocultivated with GPE cells for 35-40 d. To enhance the recovery of latent virus from the nerve tissues, each of the cocultivated tissues was transferred to a fresh monolayer culture every 7-10 d or until virus induced CPE was observed. All of the recovered viruses from nerve tissues were typed by the methods described[19].

**RESULTS**

Effect of FMAU on guinea pig GL during acute infection Four groups were treated with FMAU starting 1, 2, 3, or 4 d postinfection in order to investigate the effect of initiating FMAU at different times. As shown in Fig 1, FMAU treatment starting 1 or 2 d postinfection significantly inhibited the development of GL in guinea pigs. The result of treatment starting 3 or 4 d postinfection was not statistically different from sham-treatment.
**Fig 1.** Effect of 2'-fluoro-5'-methyl-arabinosyl uracil (FMAU) vs control on jejunal lesions (GL) of guinea pigs. The GL scores in the control group were significantly less than in the FMAU group at 3 and 4 days postinfection (p<0.01). The virus inoculation was 10^8 PFU, ±SD.

**Fig 2.** Effect of FMAU and cyclophosphamide (Cy) on jejunal lesions (GL) of guinea pigs at 3 and 4 days postinfection. The GL scores in the Cy group were significantly less than in the FMAU group at 3 and 4 days postinfection (p<0.01). The virus inoculation was 10^8 PFU, ±SD.

**Effect of FMAU and Cy on GL and virus shedding during acute infection.** The FMAU group had significantly lower GL scores than the control group at 3 and 4 days postinfection (p<0.01). The virus inoculation was 10^8 PFU, ±SD.

**Effect of FMAU and Cy on GL and virus shedding during latent infection.** The FMAU group had significantly lower GL scores than the control group at 3 and 4 days postinfection (p<0.01). The virus inoculation was 10^8 PFU, ±SD.

**Table 1.** Effect of 2'-fluoro-5'-methyl-arabinosyl uracil (FMAU) and cyclophosphamide (Cy) on virus shedding from the vaginas of guinea pigs infected with HSV-1. The results are shown in Table 1.

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Virus titer (log PFU/0.1 mL)</th>
<th>after infection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>d 3</td>
<td>d 5</td>
</tr>
<tr>
<td>Control</td>
<td>2.7±2.1</td>
<td>2.4±0.5</td>
</tr>
<tr>
<td>FMAU</td>
<td>3.2±1.0</td>
<td>1.1±1.2</td>
</tr>
<tr>
<td>FMAU+Cy</td>
<td>5.5±1.0</td>
<td>0.2±0.6</td>
</tr>
<tr>
<td>Cy</td>
<td>3.3±1.4</td>
<td>2.4±1.1</td>
</tr>
</tbody>
</table>

On d 5: FMAU vs control and Cy, p<0.01. FMAU+Cy vs Cy and control, p<0.01.

On d 7: FMAU vs Cy, p<0.01.
The percentage of FMAU-treated animals with recurrent GL was significantly higher in the Cy group than in PBS controls. Some of the guinea pigs treated with 12.5 (mg/kg)/d or 50 (mg/kg)/d of FMAU and showed no clinical GL during acute infection still developed recurrent GL. Virus shedding from the vagina was seldom found during the recurrent period. One of the sham-treated, Cy-reactivated guinea pigs had virus recovered from the vagina following GL recurrence 11 d after Cy treatment was started. Another sham-treated animal in the PBS group had vaginal virus shedding 27 d after Cy treatment. At that time, this guinea pig had no apparent GL. During the 28 d observation, one or two tiny GL on the external genital skin were noticed. Most of the recurrent GL appeared for only 1 or 2 d although additional GL occurred in sequence for a period of 3-4 d (Fig 2). The earliest GL appeared 4 d after Cy treatment was started.

The percentage of FMAU-treated animals with recurrent GL was significantly higher in the Cy group than in PBS controls. Some of the guinea pigs treated with 12.5 (mg/kg)/d or 50 (mg/kg)/d of FMAU and showed no clinical GL during acute infection still developed recurrent GL. Virus shedding from the vagina was seldom found during the recurrent period. One of the sham-treated, Cy-reactivated guinea pigs had virus recovered from the vagina following GL recurrence 11 d after Cy treatment was started. Another sham-treated animal in the PBS group had vaginal virus shedding 27 d after Cy treatment. At that time, this guinea pig had no apparent GL. During the 28 d observation, one or two tiny GL on the external genital skin were noticed. Most of the recurrent GL appeared for only 1 or 2 d although additional GL occurred in sequence for a period of 3-4 d (Fig 2). The earliest GL appeared 4 d after Cy treatment was started.
at least 4 wk after starting Cy treatment. Infectious HSV-2 from SC/DRO was recovered from 9/12 Cy and 5/17 PBS treated animals by cocultivation (Tab 3). However, compared to sham-treated animals, FMAU treatment during acute infection did not significantly reduce the percentage of animals from whom latent HSV-2 was isolated by cocultivation.

Comparison of high and low dosages of Cy in the reactivation of GH As shown in Tab 4, with 50 mg/(kg-d), 8/12 animals developed GL with an average 3 d duration. There were 2/12 deaths. With 300 mg/(kg-wk), 8/11 had GH which appeared 1-2 d after Cy initiation and persisted for a longer period (average, 6 d). The same GL were not necessarily present for many days, rather in some instances one GL resolved and another appeared. In addition, with the higher dosage of Cy, there was a higher mortality with 4 out of 11 animals dying. HSV-3 was not isolated from these recurrent GL.

DISCUSSION

A previous study showed that FMAU had the most potent effect on the treatment of GH in guinea pigs when compared with acyclovir, phenolphenoformate, 1-2'-deoxy-2'-fluoro-3-D-arabinofuranosyl-5-iodoacytine, and 1-(2'-deoxy-2'-fluoro-9-D-arabinofuranosyl)-5-idoouracil. The results obtained from the current study confirmed the previous findings. However, guinea pigs treated with FMAU plus Cy showed less virus shedding from vagina than both FMAU treated and Cy alone treated animals on 7 postinfection. This observation means that, on d 7, following FMAU treatment end, the vaginal virus shedding from animals simultaneously receiving Cy could still be reduced due to the remains of FMAU effect. On d 4 of FMAU treatment end, i.e., 7 d postinfection, animals receiving FMAU plus Cy were immunosuppressed. Therefore, more virus was shed. Although Cy treatment appeared to enhance the appearance of GL in FMAU-treated guinea pigs during acute infection, the drug treated animals showed comparatively fewer GH than those animals without FMAU treatment. Thus, FMAU therapy even in immunosuppressed guinea pigs was successful in reducing the severity of GH infection.

Several studies have been concerned with experimental reactivation of latent HSV by various means, including immunosuppressive agents. Hydrocortisone and Cy have been applied to reactivate HSV in the trigeminal ganglia. To date none of these studies have been applied to evaluate herpes recurrence in drug-treated animals. In the present study, we show that Cy can reactivate HSV during latent infection, resulting in a higher incidence of GH recurrences and a higher rate of latent virus recovery from nerve tissues. With Cy treatment, we demonstrate that FMAU starting 1 d postinfection did not reduce the establishment of HSV latency in the nervous tissue of guinea pigs although clinically FMAU prevented GH formation during acute infection. The findings that FMAU did not influence the establishment of HSV latency were not surprising since HSV-2 can reach the sensory ganglia within 1-2 d after infection.

REFERENCES

3. Schinazi RF, Peters J, Sokol MK, Nahmias AC. Therapeutic activities of 1-(2'-fluoro-2-
2'-Fluor-5'-deoxy-5'-uridine and 2'-fluoro-2',5'-dideoxy-2',5'-dideoxyadenosine are antiviral agents that inhibit HSV replication in tissue culture.


Huang GD. Mechanism of antiviral action of 2'-fluoro-2',5'-dideoxy-2',5'-dideoxyadenosine in tissue culture. Antiviral Agents Chemother 1983; 24: 385

Treatment of primary acute genital herpes in guinea pigs by the intraperitoneal administration of 2'-fluoro-2',5'-dideoxy-2',5'-dideoxyadenosine. Antiviral Agents Chemother 1984; 25: 354

